New approaches to filling the gap in tuberculosis drug discovery

PLoS Medicine

Volumn 4, Issue 11, 2007, Pages 1722-1725

  Casenghi, Martina ^a   Cole, Stewart T ^b   Nathan, Carl F ^c  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b EPFL   (Switzerland)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; CLOFAZIMINE; DIAMINE; DIARYLQUINOLINE; DIPIPERIDINE DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; FAS 20013; GATIFLOXACIN; LEVOFLOXACIN; LINEZOLID; METRONIDAZOLE; MOXIFLOXACIN; NITRODIHYDRO IMIDAZOOXAZOLE DERIVATIVE; NITROIMIDAZOLE; NITROIMIDAZOLE DERIVATIVE; OPC 67683; OXAZOLE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; PIPERIDINE DERIVATIVE; PLEUROMUTILIN; PROMAZINE; PROTEASOME INHIBITOR; PROTEINASE INHIBITOR; PYRROLE; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE; SQ 609; SUDOTERB; THIOLACTOMYCIN; TMC 207; UNCLASSIFIED DRUG; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; HEALTH CARE PERSONNEL; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MEDICAL RESEARCH; MYCOBACTERIUM TUBERCULOSIS; PROBABILITY; REVIEW; TUBERCULOSIS; UNITED STATES; ARTICLE; CHEMISTRY; DRUG EFFECT; DRUG INDUSTRY; FINANCIAL MANAGEMENT; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATENT; PHARMACEUTICS;

ANTITUBERCULAR AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG INDUSTRY; HUMANS; INTELLECTUAL PROPERTY; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; RESEARCH SUPPORT AS TOPIC; TECHNOLOGY, PHARMACEUTICAL; TUBERCULOSIS;

EID: 36849006973     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0040293     Document Type: Review

References (17)

1. Nwaka S, Ridley RG (2003) Virtual drug discovery and development for neglected diseases through public-private partnerships. Nat Rev Drug Discov 2: 919-928.
2. Nwaka S, Hudson A (2006) Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov 5: 941-955.
3. Chirac P, Torreele E (2006) Global framework on essential health R&D. Lancet 367: 1560-1561.
4. Nathan C (2004) Antibiotics at the crossroads. Nature 431: 899-902.
5. Alekshun MN, Levy SB (2007) Molecular mechanisms of antibacterial multidrug resistance. Cell 128: 1037-1050.
6. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, et al. (2006) Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368: 1575-1580.
7. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL (2007) Drugs for bad bugs: Confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6: 29-40.
8. Kapczynski A, Chaifetz S, Katz Z, Benkler Y (2005) Addressing global health inequities: An open licensing approach for university innovations. Berkeley Technol Law J 20: 1031-1114.
9. Universities Allied for Essential Medicines (2006) Philadelphia consensus statement on university policies for health-related innovations. Available: http://www.essentialmedicine.org/cs/?page_id=3. Accessed 5 October 2007.
10. Vennerstrom JL, Arbe-Barnes S, Brun R, Charman SA, Chiu FC, et al. (2004) Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 430: 900-904.
11. De D, Krogstad FM, Byers LD, Krogstad DJ (1998) Structure-activity relationships for antiplasmodial activity among 7-substituted 4-aminoquinolines. J Med Chem 41: 4918-4926.
12. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, et al. (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223-227.
13. Wang J, Soisson SM, Young K, Shoop W, Kodali S, et al. (2006) Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441: 358-361.
14. McKinney JD (2000) In vivo veritas: The search for TB drug targets goes live. Nat Med 6: 1330-1333.
15. Pogge T (2005) Human rights and global health: A research program. Metaphilosophy 36: 182-209.
16. Nathan C (2007) Aligning pharmaceutical innovation with medical need. Nat Med 13: 304-308.
17. Love J (2006) Drug development incentives to improve access to essential medicines. Bull World Health Organ 84: 408.